Resources

A summary of the work led by the Diarrhea Innovations Group, housed at PATH, to submit an application to the World Health Organization's Model List of Essential Medicines for Children for the addition of co-packaged oral rehydration solution (ORS) and zinc as an individual listing. The addition of a co-packaged listing has the potential to reinforce the lifesaving benefits of ORS and zinc in managing childhood diarrhea as a cornerstone for all health care systems involved in diarrhea management.

Environmental enteric dysfunction (EED) is an intestinal disorder common among children living in low-resource settings. EED is associated with increased risk of growth stunting, cognitive deficits, and reduced responsiveness to oral vaccines. This resource provides an overview of PATH's work to develop a prototype assay to quantitate multiple markers of EED, systemic inflammation, growth hormone (GH) resistance, and micronutrients for use in EED clinical research in low-resource settings.

Cryptosporidium is an intestinal protozoan parasite that is a major cause of diarrheal disease among young children in low-resource settings. Beyond diarrheal disease, cryptosporidiosis is associated with other chronic conditions, including growth faltering, environmental enteric dysfunction, and possibly impaired cognitive development. Current therapeutic options are limited, with only one drug, nitazoxanide, approved by the United States Food and Drug Administration. There is only one drug in clinical trials against Cryptosporidium: clofazimine, a repurposed leprosy drug developed more than three decades ago. There are no vaccines for Cryptosporidium approved or in clinical development. This poster summarizes key initiatives to develop new Cryptosporidium drugs, including an overview of PATH's portfolio.

This report, developed by the Advancing Maternal Immunization (AMI) collaboration, describes the activities required in the near- and mid-to long-term to generate key evidence and achieve the necessary conditions for advancing respiratory syncytial virus (RSV) maternal immunization in low- and middle-income countries. It is a companion to AMI's Advancing RSV Maternal Immunization: A Gap Analysis Report, which describes the evidence, information, and policy needs of global and country decision-makers, public health program planners, and implementers who might be involved in decision-making and introducing maternal RSV vaccines.AMI is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV maternal immunization.